-
Study aim
-
Evaluating the effect of dexmedetomidine infusion in the aortic root before aortic cross clamp removal on myocardial protection in patients undergoing mitral valve replacement / repair.
-
Design
-
A controlled clinical trial with superiority, with parallel groups, three-way blind, randomized block method, phase 3 on 58 patients, www.randomization.com is used for randomization.
-
Settings and conduct
-
Patients scheduled for mitral valve repair or replacement were randomly assigned to either dexmedetomedine or placebo group. Before entering the operating room, blood samples will be sent to all patients to test for troponin I and creatinine kinase-MB. Within 6 hours of entering the Intensive Care Unit, 12 hours later and 24 hours after entering the Intensive Care Unit, the sample will be repeated and the results will be recorded. Also, patients' urinary output is recorded in the first 6 hours, the first 12 hours and 24 hours after surgery.
-
Participants/Inclusion and exclusion criteria
-
The study population included patients seeking mitral valve repair or replacement with a ejection fraction above 40%, and no history of supraventricular dysrhythmias, no history of cardiac surgery, nephropathy following the use of contrast agents (CIN), respiratory failure, Stroke and TIA, And coagulopathy.
-
Intervention groups
-
At the end of the surgical procedure, before removing the aortic clamp, at the root of the aorta of patients, using a cardioplegia needle, a solution of dexmedetomidine with a concentration of 4 μg / ml, at a rate of 1 μg / kg / h, for 10 minutes, Is infused.
At the end of the surgical procedure, before removing the aortic clamp, in the aortic root of patients, using a cardioplegia needle, 0.9% sodium chloride solution at a rate of 1 ml / kg / hour for 10 minutes infusion will be.
-
Main outcome variables
-
Troponin and CPK-MB changes